التجارب السريرية بالأسفل التجارب السريرية الحالية.48 دراسات في طب الجهاز الهضمي والكبد (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Comparison Of In-Home Versus In-Clinic Administration Of Subcutaneous Nivolumab Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program Jacksonville, Fla. This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients. Influence of Diet on Tissue and Body Fluids in Health and Disease Scottsdale/Phoenix, Ariz. This study aims to compare the fatty acid composition of small sample of fat (visceral and subcutaneous) removed at the time of surgery to operative outcomes and the composition calculated from the person’s dietary history and preoperative imaging with MRI/CT scans. This study will also compare the composition of pancreatic fluid collected to that of a sample of fat removed at the time of surgery to drain the collection. Furthermore, we will study the fatty acid composition of drain fluid placed at the time of surgery to that of their fat samples. A Study to Evaluate the Prevalence and Impact of Eating Disorders Among Patients with Inflammatory Bowel Disease Jacksonville, Fla. The purpose of this study is to assess the prevalence of eating disorders; specifically, Avoidant/Restrictive Food Intake Disorder (ARFID) among adult patients in the IBD clinic and compare to the patient population seen in the primary care clinics at Mayo Clinic Florida. The Olmsted NAFLD Epidemiology Study (TONES) Rochester, Minn. About this study Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public health issue in the US. It is estimated to affect 1 in 4 adults and it is most commonly found in people who are overweight or obese. Because it is a silent disease (without symptoms until end stage) and the lab tests can be normal, it can be missed in early stages. The fat in the liver can lead to inflammation and eventually scar deposition, which can progress to cirrhosis, liver cancer and need for liver transplantation. This study aims to assess how common this disease is in Olmsted County, what markers can identify the disease early to prevent progression to cirrhosis and what other medical problems occur in people with NAFLD in addition to the liver complications. We plan to enroll a large number of adults, assess their liver with state-of-the-art tests available at Mayo Clinic and follow them over several years to monitor for disease progression and other health complications. The ultimate goal of the study is to identify new markers that predict presence of fatty liver and poor health outcomes, in order to improve population health in the community. Participation eligibility Participants will be identified from the Olmsted County population age 18 or older. Inclusion criteria: 1. Adults age 18 years or older 2. Olmsted County residents at the time of study entry Exclusion criteria: 1. Pediatric population (age<18) 2. Unwilling to participate or unable to consent 3. Known liver disease other than NAFLD at the time of survey 4. Pregnant women 5. Alcohol use in excess (14 drinks or more per week for women and 21 drinks or more per week for men) Study Of Zanzalintinib In Combination With Immuno-Oncology Agents In Participants With Solid Tumors Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts. A Bio-bank for Patients with Inflammatory Bowel Disease Associated Neoplasia Rochester, Minn. The purpose of this study is to collect blood and stool samples to validate and improve the performance of stool and blood DNA markers for inflammatory bowel disease and colorectal neoplasia critical to the long-term goal of improving effectiveness of neoplasia detection in patients using non-invasive biomarkers to assist colonoscopy and radiographic screening. Cohort of Patients With Fatty Liver Disease Jacksonville, Fla. The purpose of this research is to create a registry of patients having or at risk for metabolic liver disease for investigations into the molecular pathogenesis of cirrhosis, liver cancer, and end-stage liver disease. Mucosal and Microbiota Changes During Acute Campylobacteriosis Rochester, Minn. Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 33 توجّه للصفحة 44 توجّه للصفحة 55 طلب تحديد موعد الخبرة و مراتب التصنيفالأبحاث 05/02/2026 صُنفت مايو كلينك في مدينة روتشستر بولاية مينيسوتا كأفضل مستشفى في طب الجهاز الهضمي والجراحات المَعدية المَعوية على مستوى الولايات المتحدة حسب شبكة U.S. News & World Report. اعرف المزيد عن هذا الشرف الرفيع طب الجهاز الهضمي والكبدالقسمالرئيسيالأقساممُلخّصالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءالأطباء حسب الموقع والتخصصالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثقصص المرضىالتكاليف والتأمين الصحيالأخبار من Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب موعدمُلخّصالاختبارات والتشخيصالحلات التي يتم علاجهاالأطباءالأطباء حسب الموقع والتخصصالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةالأبحاثقصص المرضىالتكاليف والتأمين الصحيالأخبار من Mayo Clinicإحالة المرضى ORG-20308333 الأقسام والمراكز الطبية طب الجهاز الهضمي والكبد